AAN 2023: Early use of Ocrevus lowers disease activity in relapsing MS
Nearly half of the people with relapsing forms of multiple sclerosis (MS) treated early with Ocrevus (ocrelizumab) in Phase 3 clinical trials showed no evidence of disease activity after up to nine years on the therapy, data show. In contrast, about one-quarter of enrolled patients who started on…